Unconfigured Ad

Collapse

Any topic/question that does not fit into the subcategories below. If you're unsure of where to put something, ask in here!

Forums Topics Posts Last Post
No forums found.
  •  
  • Time
  • Answered
  • Show
  • New Topics
Clear All
new posts
There are no conversations in this channel.
 
  • Time
  • Show
Clear All
new posts
Please log in to your account to view your subscribed posts.
  •  
  • Time
  • Answered
  • Show
  • Sort By
  • Order
Clear All
new posts
Topics Statistics Last Post
Closed, Sticky: NGS Blogs by nilshomer
Started by nilshomer, 05-08-2010, 02:19 PM
52 responses
118,222 views
0 reactions
Last Post archana87  
Started by Genohub, 01-16-2014, 05:38 PM
3 responses
4,352 views
0 reactions
Last Post ScottC
by ScottC
 
Started by Joann, 01-14-2014, 10:20 AM
0 responses
1,813 views
0 reactions
Last Post Joann
by Joann
 
Started by Dolphin22, 01-14-2014, 02:56 AM
1 response
1,439 views
0 reactions
Last Post TiborNagy  
Started by muhe1985, 01-13-2014, 06:46 PM
0 responses
5,111 views
0 reactions
Last Post muhe1985  
Started by rskr, 01-07-2014, 02:00 PM
9 responses
7,616 views
0 reactions
Last Post rskr
by rskr
 
Started by bluefin, 01-11-2014, 09:57 PM
4 responses
2,812 views
0 reactions
Last Post GenoMax
by GenoMax
 
Started by splaisan, 12-19-2013, 01:34 AM
4 responses
3,433 views
0 reactions
Last Post mikesh
by mikesh
 
Started by edm1, 01-08-2014, 07:38 AM
3 responses
2,388 views
0 reactions
Last Post edm1
by edm1
 
Started by bruce01, 01-08-2014, 09:03 AM
0 responses
1,810 views
0 reactions
Last Post bruce01
by bruce01
 
Started by lre1234, 01-07-2014, 05:30 AM
2 responses
1,506 views
0 reactions
Last Post lre1234
by lre1234
 
No topics found.
  • Time
Clear All
No photos found.
  • Time
Clear All

Webinars

Collapse

Recent Articles

Collapse

  • SEQadmin2
    Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
    by SEQadmin2



    CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

    Despite this, “CRISPR helped turn genome editing from a specialized technique into
    ...
    07-31-2026, 11:01 AM
  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    07-20-2026, 11:48 AM
  • SEQadmin2
    Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
    by SEQadmin2



    Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
    ...
    07-09-2026, 11:10 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 08-06-2026, 07:41 AM
0 responses
20 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 08-03-2026, 10:13 AM
0 responses
33 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-31-2026, 02:55 AM
0 responses
43 views
0 reactions
Last Post SEQadmin2  
Working...